

GUIDED THERAPEUTICS INC

Form 8-K

May 08, 2009

TABLE OF CONTENTS

Item 1.02. Termination of a Material Definitive Agreement.

SIGNATURES

Table of Contents

Item 1.02. **Termination of a Material Definitive Agreement.**

On May 4, 2009, InterScan, Inc., a subsidiary of Guided Therapeutics, Inc., and NIMCO, Inc. jointly agreed to end a license agreement between the two companies granting InterScan, Inc. a license to certain intellectual property related to microporation of the skin to collect interstitial fluid (ISF). Under terms of the agreement, InterScan, Inc. was paying NIMCO, Inc. approximately \$90,000 per calendar quarter for the rights. InterScan, Inc. retains the rights to intellectual property that it developed related to collection, handling and testing of ISF. The company expects a savings of approximately \$360,000 in 2009 as a result of the cancelled agreement. The intellectual property covered by the agreement is not part of Guided Therapeutics' core cancer detection business.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**GUIDED THERAPEUTICS,
INC.**

/s/ MARK L. FAUPEL

By: Mark L. Faupel, Ph.D.
CEO & President

Date: May 8, 2009